• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

In vivo evaluation and Alzheimer's disease treatment outcome of siRNA loaded dual targeting drug delivery system.
Abstract To deliver drugs to treat Alzheimer's disease (AD), nanoparticles should firstly penetrate through blood brain barrier, and then target neurons. Recently, we developed an Apo A-I and NL4 dual modified nanoparticle (ANNP) to deliver beta-amyloid converting enzyme 1 (BACE1) siRNA. Although promising in vitro results were obtained, the in vivo performance was not clear. Therefore, in this study, we further evaluated the in vivo neuroprotective effect and toxicity of the ANNP/siRNA. The ANNP/siRNA was 80.6 nm with good stability when incubated with serum. The ANNP/siRNA could target both bEnd.3 and PC12 cells...
Source: Current Pharmaceutical Biotechnology - February 4, 2019 Category: Biotechnology Authors: Zhang C, Shen L, Gu Z, Liu X, Lin H Tags: Curr Pharm Biotechnol Source Type: research